Business
Medicure Announces Appointment of David Gurvey as Chief Financial Officer
Medicure Announces Appointment of David Gurvey as Chief Financial Officer Canad...
About this update from Medicure Inc.
[{"type":"text","content":"\n \n \n \n Medicure Announces Appointment of David Gurvey as Chief Financial Officer\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n WINNIPEG, MB\n \n ,\n \n June 24, 2021\n \n /CNW/ - Medicure Inc. (\"\n \n Medicure\n \n \" or the \"\n \n Company\n \n \") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in\n \n the United States\n \n market, is pleased to announce the appointment of Mr.\n \n David Gurvey\n \n (CPA, CMA, B.Sc.) as Chief Financial Officer, effective\n \n June 28, 2021\n \n .\n \n \n Mr. Gurvey is an accomplished finance leader with an established track record of strong financial stewardship and strategically building company value. He previously held the position of Chief Financial Officer for DiaMedica Therapeutics, where he was involved in key strategic transactions contributing to growth in company value from\n \n $2.4 million\n \n to\n \n $40 million\n \n . He has the capabilities and qualifications to accelerate Medicure's growth and business strategy.\n \n \n On behalf of the Board of Directors and management,\n \n Albert D. Friesen\n \n , PhD, CEO and Chair of the Board of Directors, stated, \"We are pleased to have David join Medicure. His experience and gift of translating strategic vision into operational execution will further strengthen our ability to achieve Medicure's corporate goals and vision.\"\n \n \n \n About Medicure Inc.\n \n \n Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT\n \n ®\n \n (tirofiban hydrochloride) injection and ZYPITAMAG\n \n ®\n \n (pitavastatin) tablets in\n \n the United States\n \n , where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. (\"Marley\"), a pharmacy located in\n \n North Carolina\n \n that offers an Extended Supp...